Positron Corporation, a nuclear medicine healthcare company, has appointed Charles Conroy as COO. As COO, Mr Conroy will define and implement strategies focused on accelerating growth across the company's product portfolio.
Charles Conroy's background includes extensive experience in corporate & product strategy, partner & alliance management, licensing, acquisitions, divestitures and portfolio management. During his career, Conroy has led global business development, marketing, and operations initiatives for companies including Covidien, Eli Lilly, and Amerinet.
Conroy joins Positron's clinical and technical executive team, consisting of: Joseph Oliverio (PET), Jason Kitten (Radiopharmaceutical/Radioisotope Production) and Scott Stiffler (Pharmaceutical Automation/Product Development).
Conroy will also lead the Company's sales and marketing initiatives; focusing on revenue generation, enhancing Positron's industry position and brand recognition as a leader in nuclear medicine.
"Chuck's leadership, expertise and background of implementing an integrated global sales and marketing plan adds tremendous value in executing Positron's objectives," stated Patrick G. Rooney, CEO of Positron. "Chuck's approach and track record will greatly complement the knowledge and direction provided by each member of our executive team in executing our vertically integrated solution strategy. We are pleased with the addition of Chuck Conroy as our COO and I expect him to have a significant impact in all aspects of our business."